Brookline Capital Acquisition CORP II (BCAC) — SEC Filings
Latest SEC filings for Brookline Capital Acquisition CORP II. Recent S-1 filing on Dec 19, 2025. AI-decoded analysis of earnings, risk factors, and insider
View Brookline Capital Acquisition CORP II on SEC EDGAR
Overview
Brookline Capital Acquisition CORP II (BCAC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 19, 2025: Brookline Capital Acquisition Corp II (BCAC) filed an S-1 for an initial public offering of 10,000,000 units at $10.00 per unit, aiming to raise $100,000,000. Each unit comprises one Class A ordinary share and one right to receive one-tenth of a Class A ordinary share upon business combination. The
Sentiment Summary
Across 1 filings, the sentiment breakdown is: 1 bearish. The dominant filing sentiment for Brookline Capital Acquisition CORP II is bearish.
Filing Type Overview
Brookline Capital Acquisition CORP II (BCAC) has filed 1 S-1 with the SEC between Dec 2025.
Recent Filings (1)
-
Brookline Capital II Files S-1 for $100M SPAC IPO Targeting Healthcare, Defense
— S-1 · Dec 19, 2025 Risk: high
Brookline Capital Acquisition Corp II (BCAC) filed an S-1 for an initial public offering of 10,000,000 units at $10.00 per unit, aiming to raise $100,000,000. E
Risk Profile
Risk Assessment: Of BCAC's 1 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Key Executives
- Patrick A. Sturgeon
Industry Context
The healthcare and defense technology industries are characterized by high growth potential, significant innovation, and substantial regulatory oversight. Healthcare is driven by an aging population, advancements in biotechnology, and evolving treatment modalities. Defense technology benefits from geopolitical tensions and the increasing reliance on advanced surveillance, cybersecurity, and unmanned systems. Both sectors are capital-intensive and require deep technical expertise, making them attractive but challenging targets for SPACs.
Top Tags
SPAC (1) · IPO (1) · Dilution Risk (1) · Healthcare Industry (1) · Defense Technology (1) · Blank Check Company (1) · Conflict of Interest (1)
Key Numbers
- Total IPO proceeds: $100,000,000 — Amount to be raised from the offering of 10,000,000 units at $10.00 each.
- Number of units offered: 10,000,000 — Each unit priced at $10.00.
- Offering price per unit: $10.00 — Price for each unit consisting of one Class A ordinary share and one right.
- Placement units purchased by sponsor: 236,175 — Purchased by Brookline Capital Holdings II, LLC at $10.00 per unit.
- Aggregate purchase price for placement units: $2,361,750 — Paid by the sponsor for 236,175 placement units.
- Class B ordinary shares held by sponsor: 4,583,916 — Acquired for $25,000, representing significant potential dilution.
- Cost per Class B ordinary share for sponsor: $0.005 — Nominal price paid by the sponsor, highlighting dilution risk.
- Timeframe to complete business combination: 24 months — If not completed, public shares will be redeemed.
- Monthly payment to sponsor: $15,000 — For office space, utilities, and shared personnel support services.
- Maximum working capital loans from sponsor: $1,500,000 — Convertible into units at $10.00 per unit at lender's option.
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Brookline Capital Acquisition CORP II (BCAC)?
Brookline Capital Acquisition CORP II has 1 recent SEC filings from Dec 2025, including 1 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BCAC filings?
Across 1 filings, the sentiment breakdown is: 1 bearish. The dominant sentiment is bearish.
Where can I find Brookline Capital Acquisition CORP II SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Brookline Capital Acquisition CORP II (BCAC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Brookline Capital Acquisition CORP II?
Financial highlights for Brookline Capital Acquisition CORP II are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for BCAC?
The investment thesis for BCAC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Brookline Capital Acquisition CORP II?
Key executives identified across Brookline Capital Acquisition CORP II's filings include Patrick A. Sturgeon.
What are the main risk factors for Brookline Capital Acquisition CORP II stock?
Of BCAC's 1 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Brookline Capital Acquisition CORP II?
Forward guidance and predictions for Brookline Capital Acquisition CORP II are extracted from SEC filings as they are enriched.